Anticoagulant reversal for life-threatening bleeds - Revision history

Danbot: Add MedicationDose entries (idarucizumab, protamine, vitamin K) with SMW annotations

2026-03-20T18:53:41Z

Add MedicationDose entries (idarucizumab, protamine, vitamin K) with SMW annotations

@@ Line 77: / Line 77: @@
 *Consider [[vitamin K]] 2.5mg oral
 |}
 ==See Also==

Rossdonaldson1: /* Warfarin(Coumadin®) */

2020-01-06T23:15:46Z

Warfarin(Coumadin®)

← Older revision		Revision as of 23:15, 6 January 2020
Line 42:		Line 42:
	\|}		\|}

	===[[Warfarin]](Coumadin®)===		===[[Warfarin]] (Coumadin®)===
	{\| {{table}}		{\| {{table}}
	\| align="center" style="background:#f0f0f0;"\|'''INR'''		\| align="center" style="background:#f0f0f0;"\|'''INR'''

Rossdonaldson1: /* References */

2020-01-06T23:14:52Z

References

← Older revision		Revision as of 23:14, 6 January 2020
Line 89:		Line 89:
	*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016		*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016
	*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.		*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.
	*Savaysa prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc.; November 2015.

	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

Rossdonaldson1 at 23:14, 6 January 2020

2020-01-06T23:14:01Z

← Older revision		Revision as of 23:14, 6 January 2020
Line 89:		Line 89:
	*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016		*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016
	*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.		*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.
	*Eliquis prescribing information. Princeton, NJ: Bristol Myers Squibb; December 2012.
	*Savaysa prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc.; November 2015.		*Savaysa prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc.; November 2015.

	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

Rossdonaldson1 at 23:13, 6 January 2020

2020-01-06T23:13:26Z

← Older revision		Revision as of 23:13, 6 January 2020
Line 12:		Line 12:
	\| [[Bivalirudin]] (Angiomax®)\|\|25 min (up to 1 hr in severe renal impairment)\|\|~ 25%\|\|As above		\| [[Bivalirudin]] (Angiomax®)\|\|25 min (up to 1 hr in severe renal impairment)\|\|~ 25%\|\|As above
	\|-		\|-
	\| [[Dabigatran]] (Pradaxa®)\|\|14-17 hrs (up to 34 hrs in severe renal impairment)\|\|~ 65%\|\|		\| [[Dabigatran]]<ref>*Pradaxa prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.</ref> (Pradaxa®)\|\|14-17 hrs (up to 34 hrs in severe renal impairment)\|\|~ 65%\|\|
	*If ingested within 2 hours, administer [[activated charcoal]]		*If ingested within 2 hours, administer [[activated charcoal]]
	*[[Idarucizumab]] (Praxbind®) 5g IV		*[[Idarucizumab]] (Praxbind®) 5g IV
Line 89:		Line 89:
	*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016		*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016
	*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.		*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.

	*Pradaxa prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.
	*Eliquis prescribing information. Princeton, NJ: Bristol Myers Squibb; December 2012.		*Eliquis prescribing information. Princeton, NJ: Bristol Myers Squibb; December 2012.
	*Savaysa prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc.; November 2015.		*Savaysa prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc.; November 2015.

	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

Rossdonaldson1 at 23:11, 6 January 2020

2020-01-06T23:11:50Z

← Older revision		Revision as of 23:11, 6 January 2020
Line 89:		Line 89:
	*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016		*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016
	*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.		*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.
	*Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2014.
	*Pradaxa prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.		*Pradaxa prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.
	*Eliquis prescribing information. Princeton, NJ: Bristol Myers Squibb; December 2012.		*Eliquis prescribing information. Princeton, NJ: Bristol Myers Squibb; December 2012.

Rossdonaldson1: /* External Links */

2020-01-06T23:11:04Z

External Links

← Older revision		Revision as of 23:11, 6 January 2020
Line 83:		Line 83:

	==External Links==		==External Links==
	[https://journalfeed.org/article-a-day/2019/anticoagulant-reversal-strategies-and-coi JournalFeed Summary with Flowsheet] of ”Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel.” by Baugh et. al. from Annals 2019<ref>[https://www.ncbi.nlm.nih.gov/pubmed/31732375?dopt=AbstractPlus Baugh et al. Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Ann Emerg Med. 2019 Nov 13. pii: S0196-0644(19)31181-3]</ref>		*[https://journalfeed.org/article-a-day/2019/anticoagulant-reversal-strategies-and-coi JournalFeed Summary with Flowsheet] of ”Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel.” by Baugh et. al. from Annals 2019<ref>[https://www.ncbi.nlm.nih.gov/pubmed/31732375?dopt=AbstractPlus Baugh et al. Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Ann Emerg Med. 2019 Nov 13. pii: S0196-0644(19)31181-3]</ref>

	==References==		==References==

Hoxbox: /* External Links */

2019-12-09T11:27:05Z

External Links

← Older revision		Revision as of 11:27, 9 December 2019
Line 83:		Line 83:

	==External Links==		==External Links==
			[https://journalfeed.org/article-a-day/2019/anticoagulant-reversal-strategies-and-coi JournalFeed Summary with Flowsheet] of ”Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel.” by Baugh et. al. from Annals 2019<ref>[https://www.ncbi.nlm.nih.gov/pubmed/31732375?dopt=AbstractPlus Baugh et al. Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Ann Emerg Med. 2019 Nov 13. pii: S0196-0644(19)31181-3]</ref>

	==References==		==References==

Neil.m.young at 16:23, 1 March 2017

2017-03-01T16:23:18Z

← Older revision		Revision as of 16:23, 1 March 2017
Line 87:		Line 87:
	<references/>		<references/>
	*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016		*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016
	*Hatfield ~~left~~ and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.		*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.
	*Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2014.		*Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2014.
	*Pradaxa prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.		*Pradaxa prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.

Neil.m.young: Text replacement - " L " to " left "

2017-02-27T22:57:41Z

Text replacement - " L " to " left "

← Older revision		Revision as of 22:57, 27 February 2017
Line 87:		Line 87:
	<references/>		<references/>
	*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016		*Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016
	*Hatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.		*Hatfield left and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.
	*Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2014.		*Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2014.
	*Pradaxa prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.		*Pradaxa prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.